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Current clinical practice in cancer stratifies patients based on tumour histology to 
determine prognosis. Molecular profiling has been hailed as the path towards 
personalised care, but molecular data are still typically analysed independently of 
known clinical information. Conventional clinical and histopathological data, if used, 
are added only to improve a molecular prediction, placing a high burden upon 
molecular data to be informative in isolation. Here, we develop a novel Monte Carlo 
analysis to evaluate the usefulness of data assemblages. We applied our analysis to 
varying assemblages of clinical data and molecular data in an ovarian cancer 
dataset, evaluating their ability to discriminate one-year progression-free survival 
(PFS) and three-year overall survival (OS). We found that Cox proportional hazard 
regression models based on both data types together provided greater 
discriminative ability than either alone. In particular, we show that proteomics data 
assemblages that alone were uninformative (p=0.245 for PFS, p=0.526 for OS) 
became informative when combined with clinical information (p=0.022 for PFS, 
p=0.048 for OS). Thus, concurrent analysis of clinical and molecular data enables 
exploitation of prognosis-relevant information that may not be accessible from 
independent analysis of these data types. 
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Most current clinical oncology practice stratifies patients based on tumour histology to inform 
prognosis. Molecular analyses are heralded as the solution for personalised medicine1, yet 
most such analyses view patients in segmented populations, either comparing molecular 
signatures across clinical and pathological categories2-6 or evaluating clinicopathological 
characteristics of clusters based upon molecular features7-10. This tends to underestimate the 
proven value of clinical and pathological information. When clinical and pathological 
information is used in combination with molecular analyses, it is typically in a post-hoc 
manner, that is, attempting to improve a molecular model with clinical information11. This 
places a high burden on molecular data, as it is required to be useful in isolation before the 
sequential addition of clinicopathological data. Here, we investigate a more integrative 
approach, using ovarian cancer as an example, where we analyse molecular and clinical data 
in concert. We take the point of view that molecular data should not replace traditional 
clinical pathology, but instead add to it. 
We show the added value of molecular data in ovarian cancer, a disease with particularly 
poor prognosis: despite often initially good responses to chemotherapy, 65% die by 5 
years12,13. There are no predictive biomarkers to direct specific treatment regimens14. Most 
patients undergo costly, neurotoxic platinum plus taxane therapy, though 20-30% do not 
respond. Alternative therapy with platinum only or, less commonly, lower toxicity agents can 
sometimes be equally effective12,15-17. Thus, personalising prognosis to enable better selection 
of these treatment options would be of great benefit in ovarian cancer.  
We take advantage of the Edinburgh Ovarian Cancer Database18, a resource in which 
molecular data are available on samples with complete histopathology plus clinical outcomes. 
We develop a novel Monte Carlo approach to quantify the usefulness of different data 
assemblages and show that while proteomics data has low information content alone, 
selected informative proteomic features have high information content when viewed in the 
context of clinicopathological data.  
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Results 
We measured protein and phosphoprotein profiles of 339 clinically-annotated samples from 
the Edinburgh Ovarian Cancer Database (EOCD)18, including markers of proliferation, cell 
cycle, apoptosis, DNA damage response, estrogen signalling, and epithelial to mesenchymal 
(EMT) transition. We applied a Cox proportional hazards regression model (CPHR) for both 
progression-free survival (PFS) and overall survival (OS) to this proteomics data alone, 
clinicopathological data alone, and combined proteomics and clinicopathological data (Fig. 1a-
c; measures detailed in Table 1; data available in Supplementary Data S1 and described in 
Supplementary Table S1). The combined models had higher concordance (c-index)19 than 
either data type alone (Fig. 1d for PFS; results for OS shown in Supplementary Fig. S1), 
indicating a greater discriminative ability; however, both the proteomics and combined 
models showed significant differences in cross-validation, suggesting potential overfitting 
(Supplementary Table S2). 
We then developed a novel Monte Carlo (MC) method to assess the information content of 
variable assemblages, measuring their capacity to discriminate prognoses. We shuffled the 
values of the variables in question independently with respect to patient (Fig. 2), then built a 
CPHR, for each of 10,000 randomised datasets. A p-value was calculated as the proportion of 
randomised datasets with c-index equal to or above the actual model (one-tailed due to 
directional nature of the c-index). A high (non-significant) p-value indicates that the actual 
data discriminates prognoses little differently than does randomly assigned data, and thus 
the information content in that data assemblage is low; a low p-value indicates high 
information content and significant discriminative capacity.  
The MC analysis revealed that the proteomic data alone had low information content 
(P=0.889 for PFS, 0.617 for OS; Fig. 1e, Supplementary Fig. S1) while the clinicopathological 
data alone had high information content (P<0.0001 for both PFS and OS; Fig. 1f, 
Supplementary Fig. S1). Since we were specifically interested in whether adding proteomics 
data to the already information-rich clinicopathological data was beneficial, we shuffled only 
the proteomics data in the combined model. This confirmed that the apparent increased 
discriminative ability of the combined model was an artefact (P=0.530 for PFS, 0.117 for OS; 
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Fig. 1g, Supplementary Fig. S1). This MC result held regardless of whether the c-index from 
the full model (as in Fig. 1) or a corrected c-index based on cross-validation was used 
(Supplementary Fig. S2).  
We then applied LASSO feature selection20 to the data before building our CPHR models, to 
select only the most informative measures. Again, the combined models had greater 
discriminative ability than either individual model (Fig. 1h, Supplementary Fig. S1); this time, 
cross-validation showed no significant differences from the full models (Supplementary Table 
S2). However, the MC analysis revealed more detail: proteomics data alone still had low 
information content (P=0.245 for PFS, 0.526 for OS; Fig. 1i, Supplementary Fig. S1) and 
clinicopathological high information content (P<0.0001 for both PFS and OS; Fig. 1j, 
Supplementary Fig. S1), while the combined models now showed significantly increased 
discriminative capacity due to the added proteomics (P=0.022 for PFS, 0.048 for OS; Fig. 1k, 
Supplementary Fig. S1). Again, the MC result also held if a corrected c-index based on cross 
validation was used (Supplementary Fig. S2); thus, the significant increase was not due to 
overfitting in the context of the full model. Because only the proteomics data were shuffled in 
the combined model, the results in Figure 1i and Figure 1k are directly comparable: 
proteomics data, which alone had low information content, showed added value when used 
alongside clinicopathological information. 
This was not true for the entire proteomics profile, however (Fig. 1e compared to Fig. 1g); 
thus, only carefully selected molecular measures can significantly increase discriminative 
ability above that provided by clinicopathological information. Figure 1i-k and Supplementary 
Figure S1 show the features selected for PFS and OS, respectively.  
Discussion 
Our work demonstrates the power of concurrent integration of traditional histopathology plus 
newer molecular measures to create something greater than either alone. Using proteomic 
profiles of samples with complete clinicopathological data, we have shown how incorporating 
molecular alongside clinicopathological data improves survival analyses. In doing so, we have 
developed a novel Monte Carlo analysis to quantify the usefulness of data assemblages. 
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Machine learning methodologies in molecular analyses of cancer have been criticised for 
overfitting problems21, and we directly address this problem with our Monte Carlo analysis. 
We reveal data assemblages with low information content yet high performance, whose 
performance must then be due to overfitting. Where 10-fold cross validation of the c-index 
suggested overfitting issues, our MC analysis agreed, showing low information content for 
both proteomics alone and combined datasets with no feature selection. However, our MC 
analysis provided further information where cross-validation showed no significant 
differences, revealing low information content in selected proteomics features alone. Only 
when these proteomics features were combined with selected clinical features did they prove 
to be informative.  
We found that feature selection before survival analysis is key to producing sensible 
information out of the molecular data. Using all available proteomic measures in addition to 
clinicopathological data at first appears to increase the discriminatory ability of survival 
analysis, but this is in fact due to overfitting. However, if feature selection is first applied, the 
addition of proteomic to clinicopathological data significantly increases the discriminatory 
ability of our CPHR model. The measures selected provide insights into the biology of ovarian 
cancer. E-cadherin is related to cell adhesion, and its loss has been reported to be associated 
with poor survival22-24. Caspase-3 perhaps indicates benefits of propensity to apoptosis, and 
has been associated with more favourable patient outcomes25,26. pH2AX is a marker of DNA 
damage repair, while expression of the Wilms’ tumour 1 (WT1) gene has been associated 
with poor prognosis in ovarian cancer27,28. In contrast, nuclear beta-catenin expression has 
been associated with favourable outcomes in this disease29-31. 
There is merit in further examination of the data, because the details reveal important 
features. Comparing Figure 1d and 1h reveals that the CPHR models that contain all the 
proteomic data are more discriminatory (higher c-index) than those with only selected 
proteomic measures; however, we know this is due to overfitting from the MC analysis (Fig. 
1g). Yet even the selected proteomics measures alone have poor discrimination (c-index 
close to 0.5) and non-significant MC p-values (Fig. 1i), indicating low information content. 
Only when these selected proteomics measures are combined with clinicopathological 
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measures do we see improvement in the c-index and significant information content revealed 
by MC analysis (Fig. 1k). In particular, this MC analysis is directly comparable to that with 
just proteomics: since only the proteomics variables are shuffled, only the information 
content of these proteomics measures are revealed. Thus, the information content of the 
proteomics differs depending on the context. The proteomic data, which alone was 
uninformative, added value when used alongside clinicopathological information.  
The above shows the power of our MC approach for assessing data assemblages. The 
information content of a data set can be assessed as a whole by shuffling all variables; 
alternatively, shuffling only those additional variables assesses the benefit of adding specific 
measurements to an already useful group of features. Thus, we present a method of 
quantifying usefulness of measures when direct success of a model may be less meaningful 
due to overfitting concerns. This quantification methodology could be applied to evaluate the 
discriminative ability of features used to assess patient outcome in many diseases, a 
necessary step for personalised medicine. 
Our work demonstrates the path towards a systems pathology approach for personalised 
medicine. We move beyond sequential application of clinicopathological and molecular data to 
stratify groups or to refine models. We analyse proteomics data in concert with traditional 
histology and clinical measures, enabling better discrimination than either alone. This was 
true even though the proteomics data was uninformative alone, a stage at which many such 
molecular studies might otherwise be abandoned. Our Monte Carlo-based assessment of 
information content can quantify the added value of new data, thus both enabling the 
identification of beneficial variable additions and avoiding overfitting. Our results generalise 
to other diseases where long-established pathological analyses already produce valuable 
information that should not be ignored. 
Methods 
Study Population 
Formalin-fixed, paraffin-embedded ovarian tumour samples were obtained from the 
Edinburgh Ovarian Cancer Database (EOCD) as previously described8,18. The data set 
 7 
consisted of 339 samples, which form a subset of those analysed in Faratian et al8. This 
research was approved by the Lothian Research Ethics Committee (08/S1101/41).  
Clinicopathological Measures 
Samples in the EOCD were annotated with clinicopathological information which were divided 
into “input” measures – those relating to patient, disease, and treatment characteristics – 
and “output” measures – those relating to survival. A summary of the clinicopathological 
measures is shown in Table 1; data are available in Supplementary Data S1 and described in 
Supplementary Table S1. The output measure of progression-free survival (PFS) represents 
the number of days between the start of treatment and the first signs of cancer recurrence; 
overall survival (OS) represents the number of days between the first histological diagnosis 
and the day of death. Both survival measures were right-censored.  
Proteomic Measures 
Proteins and subcellular location measured are shown in Table 1. Protein and phosphoprotein 
levels were obtained by automated quantitative immunofluorescence using carefully validated 
antibodies as previously described8. Briefly, tissue microarrays were constructed using 
triplicate samples from each tumour. Immunofluorescence detection of phosphoprotein and 
other targets was performed using methods previously described8,32; antibodies and 
conditions used are shown in Supplementary Table S3. Pan-cytokeratin antibody was used to 
identify infiltrating tumour cells, DAPI counterstain to identify nuclei, and Cy-5-tyramide 
detection of target for compartmentalised (tissue and subcellular) analysis of tissue sections. 
Monochromatic images of each TMA core were captured at x20 objective using an Olympus 
AX-51 epifluorescence microscope, and high-resolution digital images analysed by the 
AQUAnalysisTM software. If the epithelium comprised <5% of total core area, the core was 
excluded from analysis. Protein and phosphoprotein expression was quantified by calculating 
the Cy5 fluorescence signal intensity on a scale of 0–255 within each image pixel, and the 
AQUA score generated by dividing the sum of Cy5 signal within the epithelium by the area of 
the cytoplasm or nucleus for cytoplasmic or nuclear measurements, respectively. AQUA 
scores were averaged from triplicate cores and mean values obtained.  
Survival Analysis 
Cox proportional hazards regression (CHPR) was applied to clinicopathological inputs and 
proteomic measures, using the cph function in the R package rms (Breslow method; x and y 
set to ‘TRUE’ for use in cross-validation, below), to predict both PFS and OS. Models without 
feature selection were full multivariate models using all measures in Table 1; models using 
LASSO feature selection were multivariate models including those features as noted in Figure 
1 and Supplementary Figure S1. Validity of the proportional hazards assumption was 
assessed using visual inspection of plots from the R functions survplot and cox.zph, and 
examination of statistics of Schoenfeld residuals. Coefficients with 95% confidence intervals 
and associated Schoenfeld residual statistics for all models are presented in Supplementary 
Table S4. CPHR models were assessed using the concordance index (c-index)19, available 
from the R function validate. The c-index represents the probability that, for two randomly 
chosen patients, the model correctly orders the patients in their outcome measure (here PFS 
and OS). Ten-fold cross-validation was performed computing the c-index for each resample 
(dxy=’TRUE’), and repeated 100 times to provide average performance in cross-validation.  
Feature Selection 
Feature selection was performed using the least absolute shrinkage and selection operator 
(LASSO)20 to identify the most informative features for OS and PFS. LASSO was applied using 
functions optL1 and profL1 in the R package penalized (and verified with glmnet); the 
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sparsity parameter (λ) was obtained by a likelihood cross-validation with settings: 10-folds 
and the sparsity parameter lies in the interval: 0.001<λ<50.  
Monte Carlo Analysis 
We developed a novel Monte Carlo analysis to evaluate information content of any variable 
assemblage. Figure 2 describes the shuffling methodology graphically: each variable is 
shuffled independently of all others and of patient outcome; all variables or a subset can be 
shuffled to analyse the information content of the entire assemblage or a particular group, 
respectively. This methodology can be applied with any analysis method that provides a 
scalar performance measure; we applied it to CHPR models evaluated via the c-index (see 
Results). R code to perform our Monte Carlo analysis for CHPR models is provided as 
Supplementary Data S2; an example vignette applying it to our data is available as 
Supplementary Note S1. 
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Figures Legends 
Figure 1. Added value of proteomics for predicting progression-free survival. (a-c) 
Example images representing proteomics, a fluorescence AQUA image (a), clinicopathology, 
a histological slice (b), and the combination (c). (d) C-index of Cox proportional hazards 
regression models for proteomics data only, clinicopathological data only, and combined 
proteomics and clinicopathological data. (e-g) Corresponding Monte Carlo (MC) analyses 
showing histograms of c-index from 10,000 randomised datasets; value of the actual analysis 
is highlighted and its p-value indicated (*-significant); histogram bars are coloured green 
below the actual value and pink above. (h-k) As for (d-g) after LASSO feature selection; 
selected features shown below MC histograms in order of decreasing hazard ratio. Note only 
proteomics data was randomised in (g) and (k). 
Figure 2. Shuffling methodology for novel Monte Carlo analysis. (a) Graphical 
representation of a dataset with patient outcome in the leftmost column and the remainder of 
the columns representing predictor variables; each row is coloured uniquely in a gradient to 
represent data from an individual patient for illustrative purposes. (b) For the Monte Carlo 
analysis, the values of each variable are shuffled, randomising that single variable with 
respect to patient outcome; this is carried out independently for each variable such that 
correspondence both between a variable and outcome, and among variables, is broken. Note 
this differs from standard Monte Carlo analyses, which would shuffle only patient outcome 
with respect to predictors, thus maintaining correspondence among variables. (c) The 
shuffling procedure can also be performed on a subset of variables, to evaluate only the 
added value of these variables. 
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Tables 
Table 1. Clinicopathological and proteomic measures. 
Clinicopathological Proteomic 
   Measured in 
Measure Values Protein/phosphoprotein Nucleus Cytoplasm 
inputs  pERK x  
age continuous (days) pβCatenin x  
 stratified < > 50 years pSTAT3 (Ser727) x  
histopathology papillary serous pSTAT3 (Ser705) x  
 clear cell pNFkB x  
 endometriod pRB  x  
 mixed histology pH2AX x  
 mucinous pBRCA1 x  
 adenocarcinoma p-p53  x  
stage stage 1 Ki67 x  
 stage 2 phosphohistone H3 (pHH3) x  
 stage 3 cleaved caspase-3 x  
 stage 4 WT1 x  
regimen platinum Snail  x 
 platinum + taxane Slug  x 
outputs  E-cadherin  x 
progression-
free survival 
continuous (days) estrogen receptor-β 1 
(ERβ1) 
x x 
overall survival continuous (days) estrogen receptor-β 2 
(ERβ2) 
x x 
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